Alerts will be sent to your verified email
Verify Email
WOCKPHARMA
|
Wockhardt
|
Eris Lifesciences
|
Pfizer
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
10.6 % | 6.1 % | 4.8 % |
|
R&D as a % of Total Sales
|
3.7 % | 0.0 | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-3.51 % | 17.74 % | 19.03 % |
|
5yr average Equity Multiplier
|
2.02 | 1.76 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.39 | 0.51 | 0.6 |
|
5yr Avg Net Profit Margin
|
-4.28 % | 22.76 % | 26.04 % |
|
Price to Book
|
5.03 | 7.62 | 5.62 |
|
P/E
|
0.0 | 56.2 | 29.29 |
|
5yr Avg Cash Conversion Cycle
|
-94.15 Days | -54.68 Days | 21.86 Days |
|
Inventory Days
|
61.29 Days | 27.48 Days | 49.93 Days |
|
Days Receivable
|
60.36 Days | 54.07 Days | 29.1 Days |
|
Days Payable
|
251.45 Days | 148.48 Days | 77.28 Days |
|
5yr Average Interest Coverage Ratio
|
-0.43 | 66.44 | 185.18 |
|
5yr Avg ROCE
|
-0.28 % | 18.34 % | 23.84 % |
|
5yr Avg Operating Profit Margin
|
5.03 % | 34.43 % | 31.72 % |
|
5 yr average Debt to Equity
|
0.56 | 0.46 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | -0.19 % | 76.68 % |
|
5yr Average Return on Assets
|
-1.79 % | 12.4 % | 15.25 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
49.08 % | 54.85 % | 63.92 % |
|
Share Pledged by Promoters
|
21.3 % | 16.92 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-14.75 % | 2.56 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
7.86 % | 6.95 % | 5.23 % |
|
Wockhardt
|
Eris Lifesciences
|
Pfizer
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|